KPD Consolidation After ASCT in NDMM Patients

This study aims to evaluate the efficacy and safety of post-transplant consolidation therapy with the KPD regimen (carfilzomib, pomalidomide, and dexamethasone) versus no consolidation, followed by maintenance therapy, in patients with transplant-eligible newly diagnosed multiple myeloma (TE-NDMM). The primary goal is to compare minimal residual disease (MRD) negativity rates and overall treatment outcomes between the two groups.

NCT Number	NCT06879379
Lead Sponsor	Peking University People's Hospital
Conditions	Multiple Myeloma, Newly Diagnosed
Enrollment	202 participants
Start Date	2025-03
Primary Completion	2028-03 (estimated)
Study Completion	2029-03 (estimated)
Updated on ClinicalTrials.gov	2025-03-17